Evidence in favour
- 31 distinct acquisition events survive duplicate and security-type controls.
- Participation spans 20 named insiders rather than one filing source.
- The latest qualifying evidence is fresh, dated 15 Sep 2026.
Company insider dossier
Incyte Corporation insider intelligence
INCY filings assessed for conviction, transaction quality, insider breadth, clustering, freshness, and price confirmation.
64/100
Accumulation bias
92/100 confidence- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Latest evidence
- 15 Sep 2026
Investment committee read
Accumulation bias
Priced common-share acquisitions carry more weighted evidence than disposals after freshness, role, size, and duplicate controls.
Watch for market confirmationDecision risks
- Qualifying disposal events outnumber acquisitions, although disposals receive a lower directional weight.
Price confirmation map
Weekly price with common-share events
Acquisitions and disposals are aligned to the nearest completed weekly bar.
Mar 2025Sep 2026
Weekly closeCommon-share acquisitionCommon-share disposal
Market confirmation
Price and trend context
- Latest close
- 125.31 USD
- One-week move
- +3.2%
- Four-week move
- -2.0%
- Fair-value gap
- +61.2%
- Trend signal
- Active
- Relative strength
- 9.1
Directional balance
Controlled event mix
41.9%acquisition
- Acquisition events
- 31
- Disposal events
- 43
- Net value
- -$21.9M
Cadence
Twelve-week filing pressure
Volume shows attention. Controlled events determine direction.
006 Jul
3813 Jul
420 Jul
4127 Jul
703 Aug
110 Aug
117 Aug
124 Aug
031 Aug
007 Sep
1014 Sep
021 Sep
Named participants
Insider conviction by person
HARRIGAN, EDMUNDDirector752 events
CLANCY, PAUL JDirector744 events
BAKER, BROS. ADVISORS LPDirector, 10% Owner721 events
MAYES, PATRICK AEVP & Chief Scientific Officer6933 events
CAGNONI, PABLO JPresident, Global Head of R&D6216 events
BIENAIME, JEAN JACQUESDirector612 events
BRAWLEY, OTIS WDirector500 events
FOUSE, JACQUALYN ADirector500 events
GARDNER, DAVID HEVP, Chief Strategy Officer500 events
HEESON, LEEEVP, Head of Incyte Intl500 events
HIGH, KATHERINE ADirector500 events
HOFFMAN, RICHARD A.EVP & General Counsel500 events
Evidence quality
Security and transaction context
Role architecture
Who is participating
Transaction evidence
Auditable INCY filing ledger
Showing 31 to 60 of 154.
MAYES, PATRICK AEVP & Chief Scientific Officer
DisposalOptions and derivatives
2072 sharesEmployee Stock Option (right to buy)
Not reportedContext evidence
MAYES, PATRICK AEVP & Chief Scientific Officer
DisposalOptions and derivatives
9459 sharesEmployee Stock Option (right to buy)
Not reportedContext evidence
MAYES, PATRICK AEVP & Chief Scientific Officer
DisposalOptions and derivatives
2864 sharesEmployee Stock Option (right to buy)
Not reportedContext evidence
MAYES, PATRICK AEVP & Chief Scientific Officer
DisposalOptions and derivatives
3023 sharesEmployee Stock Option (right to buy)
Not reportedContext evidence
CAGNONI, PABLO JPresident, Global Head of R&D
DisposalCommon equity
15888 sharesCommon Stock
$1.9MDirectional evidence
MAYES, PATRICK AEVP & Chief Scientific Officer
DisposalCommon equity
14661 sharesCommon Stock
$1.8MDirectional evidence
MAYES, PATRICK AEVP & Chief Scientific Officer
DisposalCommon equity
6171 sharesCommon Stock
$737.0KDirectional evidence
MAYES, PATRICK AEVP & Chief Scientific Officer
AcquisitionCommon equity
9459 sharesCommon Stock
$683.6KDirectional evidence
MAYES, PATRICK AEVP & Chief Scientific Officer
DisposalCommon equity
5332 sharesCommon Stock
$636.7KDirectional evidence
MAYES, PATRICK AEVP & Chief Scientific Officer
DisposalCommon equity
4695 sharesCommon Stock
$560.5KDirectional evidence
MAYES, PATRICK AEVP & Chief Scientific Officer
DisposalCommon equity
2864 sharesCommon Stock
$342.0KDirectional evidence
MAYES, PATRICK AEVP & Chief Scientific Officer
DisposalCommon equity
2293 sharesCommon Stock
$273.8KDirectional evidence
MAYES, PATRICK AEVP & Chief Scientific Officer
DisposalCommon equity
2187 sharesCommon Stock
$261.3KDirectional evidence
MAYES, PATRICK AEVP & Chief Scientific Officer
AcquisitionCommon equity
3023 sharesCommon Stock
$251.5KDirectional evidence
MAYES, PATRICK AEVP & Chief Scientific Officer
AcquisitionCommon equity
2864 sharesCommon Stock
$222.4KDirectional evidence
MAYES, PATRICK AEVP & Chief Scientific Officer
AcquisitionCommon equity
2623 sharesCommon Stock
$219.2KDirectional evidence
MAYES, PATRICK AEVP & Chief Scientific Officer
AcquisitionCommon equity
3148 sharesCommon Stock
$216.0KDirectional evidence
MAYES, PATRICK AEVP & Chief Scientific Officer
AcquisitionCommon equity
2293 sharesCommon Stock
$207.7KDirectional evidence
MAYES, PATRICK AEVP & Chief Scientific Officer
DisposalCommon equity
1643 sharesCommon Stock
$196.4KDirectional evidence
MAYES, PATRICK AEVP & Chief Scientific Officer
AcquisitionCommon equity
2623 sharesCommon Stock
$196.1KDirectional evidence
MAYES, PATRICK AEVP & Chief Scientific Officer
DisposalCommon equity
1642 sharesCommon Stock
$196.0KDirectional evidence
MAYES, PATRICK AEVP & Chief Scientific Officer
AcquisitionCommon equity
2918 sharesCommon Stock
$178.5KDirectional evidence
MAYES, PATRICK AEVP & Chief Scientific Officer
AcquisitionCommon equity
2709 sharesCommon Stock
$167.3KDirectional evidence
MAYES, PATRICK AEVP & Chief Scientific Officer
AcquisitionCommon equity
2072 sharesCommon Stock
$149.0KDirectional evidence
MAYES, PATRICK AEVP & Chief Scientific Officer
AcquisitionCommon equity
2284 sharesCommon Stock
$146.7KDirectional evidence
MAYES, PATRICK AEVP & Chief Scientific Officer
AcquisitionCommon equity
1642 sharesCommon Stock
$139.6KDirectional evidence
MAYES, PATRICK AEVP & Chief Scientific Officer
AcquisitionCommon equity
1643 sharesCommon Stock
$132.3KDirectional evidence
MAYES, PATRICK AEVP & Chief Scientific Officer
DisposalCommon equity
326 sharesCommon Stock
$39.7KDirectional evidence
MAYES, PATRICK AEVP & Chief Scientific Officer
AcquisitionCommon equity
326 sharesCommon Stock
$34.4KDirectional evidence
MAYES, PATRICK AEVP & Chief Scientific Officer
DisposalCommon equity
85 sharesCommon Stock
$10.4KDirectional evidence
Reading the dossier
Direction and confidence are separate
Conviction
The 0 to 100 score classifies deduplicated priced common-share evidence. Fifty is balanced or non-directional.
Confidence
Confidence rises with controlled event depth, named-insider breadth, fresh evidence, normalized values, and a longer observation span.
Disposals
Selling is not treated as the mirror image of buying. It carries less directional weight because taxes, diversification, compensation, and planned transactions can all create sales.
Price confirmation
The market chart tests whether the filing thesis is being confirmed or rejected by price, fair-value position, relative strength, and the current trend state.
Independent market research for education. This classification is not investment advice, a recommendation, a forecast, or an execution instruction.